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Abstract
Background: The phase and amplitude of rhythms in physiology and behavior are generated by circadian oscillators and
entrained to the 24-h day by exposure to the light-dark cycle and feedback from the sleep-wake cycle. The extent to which
the phase and amplitude of multiple rhythms are similarly affected during altered timing of light exposure and the sleep-
wake cycle has not been fully characterized.
Methodology/Principal Findings: We assessed the phase and amplitude of the rhythms of melatonin, core body
temperature, cortisol, alertness, performance and sleep after a perturbation of entrainment by a gradual advance of the
sleep-wake schedule (10 h in 5 days) and associated light-dark cycle in 14 healthy men. The light-dark cycle consisted either
of moderate intensity ‘room’ light (,90–150 lux) or moderate light supplemented with bright light (,10,000 lux) for 5 to
8 hours following sleep. After the advance of the sleep-wake schedule in moderate light, no significant advance of the
melatonin rhythm was observed whereas, after bright light supplementation the phase advance was 8.1 h (SEM 0.7 h).
Individual differences in phase shifts correlated across variables. The amplitude of the melatonin rhythm assessed under
constant conditions was reduced after moderate light by 54% (17–94%) and after bright light by 52% (range 12–84%), as
compared to the amplitude at baseline in the presence of a sleep-wake cycle. Individual differences in amplitude reduction
of the melatonin rhythm correlated with the amplitude of body temperature, cortisol and alertness.
Conclusions/Significance: Alterations in the timing of the sleep-wake cycle and associated bright or moderate light
exposure can lead to changes in phase and reduction of circadian amplitude which are consistent across multiple variables
but differ between individuals. These data have implications for our understanding of circadian organization and the
negative health outcomes associated with shift-work, jet-lag and exposure to artificial light.
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In humans, circadian rhythms in a variety of physiological and
behavioral variables including core body temperature, urine
production, hormones subjective alertness, cognitive performance,
short-term memory, sleep propensity and sleep structure have
been described (reviewed in [1,2]). Under normal conditions, these
rhythms are synchronized to the 24-h solar day and to each other,
and exhibit specific phase relationships with the light-dark/
activity-rest cycle, and with each other. For instance, plasma
melatonin crests in the middle of the habitual dark/sleep episode,
approximately two hours before the nadir of the core body
temperature rhythm and approximately 4–6 hours before the crest
of the cortisol rhythm. Many of these rhythms persist during
sustained wakefulness under constant environmental and behav-
ioral conditions. According to current understanding of circadian
organization in mammals, all these rhythms are driven by a central
circadian pacemaker located in the suprachiasmatic nucleus (SCN)
of the hypothalamus, which coordinates multiple circadian
oscillators in the periphery [3]. Single SCN neurons are competent
circadian oscillators [4], and some of the genes involved in the
generation of circadian rhythmicity have been identified [3].
The SCN receives light input from both classical photoreceptors
(rods and cones), as well as from a more recently identified subset
of intrinsically-photosensitive retinal ganglion cells [5,6]. The
phase (timing) of these endogenous circadian rhythms can be
changed by an acute shift of the light-dark cycle [7]. The largest
phase advances (shifts to an earlier time) are observed when light is
administered in the late subjective night/early subjective morning,
shortly after the core body temperature nadir, which in a young
man sleeping from 00:00–08:00 would be approximately 06:00 h.
Although in some prior experiments phase shifts were assessed for
multiple variables and found to be equivalent [8,9] few
experiments have investigated whether individual differences in
phase shifts are similar for a multitude of variables.
Circadian phase resetting by light is in general not thought to be
accompanied by a change in the amplitude of circadian rhythms,
and the negative consequences of circadian desynchrony are
typically discussed within the framework of circadian phase rather
than amplitude. Circadian amplitude reduction has, however,
been observed when light is carefully timed to drive the oscillator
to its singularity [10–12] but those findings and their interpretation
remain controversial [13]. Whether individual differences in
amplitude reduction are similar across endocrine and behavioral
variables is currently not known. Although phase-shifting of the
human circadian system was once thought to require bright light,
dose-response studies indicate that the pacemaker is sensitive to
moderate light, i.e. intensities typically observed in artificially lit
living rooms or offices [14], both in the phase advance [15] and
phase delay [16] regions of the phase response curve to light. A
similar sensitivity is observed for the acute suppression of
melatonin by light [14,16] and the acute alerting effect of light
[17]. Together, these studies indicate that the drive onto the
pacemaker exerted by moderate light (,100–150 lux) appears to
be nearly half of the drive exerted by much brighter light
(,10,000 lux) [16]. The effect of a light stimulus is, however, also
dependent on the prior history of light exposure [18–20], and to
what extent moderate intensity light can affect multiple circadian
rhythms remains unclear.
There is evidence to suggest that in addition to ocular light
exposure, nonphotic stimuli, such as an imposed rest-activity cycle,
also affect the phase of human circadian rhythms of melatonin,
body temperature and other variables [21,22]. Furthermore, it is
well established that the rest-activity cycle and associated light-
dark cycle also contribute to the observed amplitude of many
variables, such as core body temperature, alertness and many
endocrine variables [1].
The recent insights into the sensitivity of the human circadian
pacemaker to photic and non-photic stimuli, and the emerging
complexity of circadian organization led us to re-analyze phase
resetting and amplitude effects of the sleep-wake and light-dark
cycles on multiple endocrine, physiologic and behavioral variables.
In particular, we aimed to investigate to what extent altered timing
of the sleep-wake cycle and associated room and bright light cycles
could affect the phase and amplitude of multiple circadian
rhythms, and how changes in those rhythms correlated within
individuals and differed between individuals.
Materials and Methods
Objectives
To investigate the extent to which the sleep-wake cycle and
associated moderate and bright light exposure can affect the phase
and amplitude of multiple circadian rhythms, and the extent to
which individual differences in changes in phase and amplitude
are correlated across variables. We selected a protocol in which the
sleep-wake and light-dark cycle were advanced gradually to
accomplish a 10-h phase-advance over a five day interval. This
protocol is different from the most commonly used protocols in
which the organization of the human circadian system is
investigated by an acute shift of the sleep-wake cycle and the
associated light-dark cycle. The protocol is also different from
those few studies in which a gradually advancing sleep-wake
schedule was used, because in those studies the daily advance was
either shorter (30 min [23] or 60 min [24]) or imposed for only 3
days [25].
Participants and screening
Data were obtained from 14 male participants [25.8 (2.7) (SEM)
years], who were free of sleep complaints as assessed by a sleep
disorders questionnaire, and in good physical and mental health.
Extreme chronotypes [26] were excluded.
Ethics
The experimental procedures and the procedure for obtaining
informed consent were approved by the Brigham and Women’s
Hospital Human Research Committee, and the study was con-
ducted in accordance with the principles outlined in the De-
claration of Helsinki. Before participation, every subject received a
description of the procedure and general purpose of the
experiment and provided written informed consent.
Protocol
The study used a parallel group design, with seven participants
in each group (moderate light group and bright light group), with
the experimental protocol as shown in Fig. 1. Following two
baseline days with 8-h sleep episodes scheduled from 00:00 to
08:00 h, the sleep-wake schedule was advanced such that after 5
days the sleep episodes were scheduled from 14:00 to 22:00. The
10-h advance was achieved gradually by scheduling the sleep
episodes (SP) as follows: SP 3 (duration 6 h): 22:00 to 04:00 h; SP
4 (duration 7 h): 20:00 to 03:00 h; SP 5 (duration 7 h): 18:00 to
01:00 h; SP 6 (duration 8 h): 16:00 to 00:00 h; SP 7 and 8
(duration 8 h): 14:00 to 22:00 h. During scheduled sleep episodes,
participants were in the dark (,0.03 lux) and were required to
remain supine in bed. During waking hours the participants were
exposed to moderate light (,100–150 lux), with interventional
exceptions as noted below.
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indoor light (,10,000 lux) for 5 to 8 hours each day on Days 4–8.
The exact timing and duration of the overall daily light exposure
was designed according to a mathematical model [27–29] to
optimize the drive onto the circadian pacemaker. In this model, a
low stiffness van Der Pol oscillator is influenced by light. The drive
of light onto the pacemaker is I
1/3 and maximum sensitivity to
light occurs at the minimum of the core body temperature (CBT)
rhythm, which on average occurs 1–2 hours before habitual wake
time. In this model, light pulses centred after the CBT minimum
will lead to phase advance shifts. The lighting schedule was
designed primarily to impact the phase advance portion of the
phase response curve on the five study days during which the
bright light was presented, and to be robust against inter and intra-
individual differences in circadian phase. To accomplish this, the
duration of the bright light exposure was 5, 5, 6, 7.5 and 8 h in the
early part of the waking episode on study days 4, 5, 6, 7 and 8
respectively. Bright light exposure was initiated 1 h after scheduled
wake time on each of these days, with the exception of study day 7,
when it was initiated 0.5 h after scheduled wake time. Thus, the
timing and duration of the light pulses was such that even if
considerable intra and inter individual differences in circadian
phase were to occur, the center of the bright light pulse would
likely be located after the CBTmin so as to induce a phase advance
shift. Participants in the moderate light group remained in ,100–
150 lux of light during the hours that the bright light group were
exposed to bright light. The protocol was designed to facilitate
adaptation of astronauts during the pre-launch interval to a
schedule required in preparation for a night launch of the space
shuttle, as first implemented for STS-35 in 1990 [30]. Because
astronauts had to participate in daily operational simulations
during the pre-launch interval, all study participants were exposed
to dim light conditions (,5–15 lux) for four hours each day to
simulate this training. The dim light exposure was scheduled so
that the phase delay portion of the phase response curve received
as little light as possible. The 4-h episode of dim light exposure
started 6 h prior to SP 4, and 5 h prior to SP 5–8. After
completion of the 10-h phase advance of the sleep-wake schedule,
a 48-h constant routine was performed on study days 9–10 to
assess the phase and amplitude of circadian rhythms.
Exposure to bright light
During bright light exposure, light levels were increased to
,10,000 lux. To minimize subject discomfort related to sudden
changes in illuminance, bright light exposure episodes were
preceded and followed by a 25-min episode during which time
illuminance was gradually increased or reduced in 5 steps. The
bright light was provided by ordinary wall-mounted fluorescent
‘cool white’ lamps. The fixtures covered the wall from floor to
ceiling with 8-foot lamps arranged vertically. Light levels during
bright light episodes were monitored and recorded every
10 minutes with a research photometer (International Light,
Peabody, MA and Sper Scientific, Tempe, AZ). The detector
was placed on the subject’s forehead in the line of gaze. Both
groups of participants wore clear, ultraviolet-filtering polycarbon-
ate Ultra-Spec 2000 safety goggles with 4C coating (UVEX
Winter Optical, Smithfield, RI) throughout bright light or room-
light control exposures.
Constant routine
The constant routine method was used to unmask the
endogenous circadian component of the physiologic and behav-
ioral rhythms [31]. During the constant routine, participants were
restricted to a regimen of semi-recumbent posture, low activity,
and continuous wakefulness in constant indoor lighting (90–
150 lux). Wakefulness was enforced by a technician present in the
room and verified by continuous polysomnographic recording.
Daily nutritional and electrolyte needs were met by identical
hourly snacks.
Figure 1. Raster plot of the experimental protocol. During the two baseline days sleep episodes were scheduled from 00:00 to 08:00
Thereafter, the sleep-wake schedule was advanced gradually resulting in a 10 hour advance of the sleep-wake schedule. Sleep episodes on day seven
and eight were scheduled from 14:00 to 22.00. During scheduled sleep episodes, participants were exposed to darkness (,0.02 lux). During waking
hours the participants were exposed to ,90–150 lux moderate light. During the bright light treatment episodes, the moderate light participants
remained in moderate light, whereas the bright light treatment participants received ,10,000 lux of light. Both moderate light and bright light
treated participants participated in dim light work simulations.
doi:10.1371/journal.pone.0030037.g001
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collection
Blood samples were collected 1–3 times per hour via an
indwelling forearm catheter connected to a 12-foot IV line (Liberty
Medical LLC, Sterling, VA) during the baseline day (Study Day 2)
and during the constant routine (Study Day 8–10). Samples were
placed on ice and centrifuged within one hour of collection, and
the plasma was frozen at 220uC. Hourly samples were assayed for
plasma melatonin concentrations using a radioimmunoassay
(Pharmasan Labs, Inc., Osceola, WI). Assay sensitivity was
7 pmol/L, intra-assay and inter-assay coefficients of variations
were 8% and 15%, respectively. Blood samples obtained at 20 min
intervals were assayed for plasma cortisol using a radioimmuno-
sassay.
Core body temperature was collected at one minute intervals by
a disposable thermistor (Measurement Specialites, Inc, Hampton,
VA) inserted ,10 cm into the rectum.
Polysomnographic recordings
During all scheduled sleep episodes, electroencephalograms
(C3-A2, C4-A1, O1-A2, O2-A1), submental electromyogram and
electrocardiogram were recorded with a Nihon Kohden- 5208 or
4418 electroencephalograph. The signals were also digitized and
stored on a Sun-386i work station on which the Nicolet-Ultra-Som
sleep analysis was implemented (Nicolet Corp., Madison, WI).
Polysomnograms of the 7th and 8th sleep episode were scored
manually (DBB, DJD) in 30s epochs according to established
criteria [32].
Neurobehavioral performance assessment
Subjective alertness was measured three times per waking hour
using a linear, nonnumeric, 100-mm bipolar (sleepy - alert) visual
analog scale. Cognitive performance was assessed hourly by
administering a calculation test consisting of 125 random pairs of
two digit numbers. The subject was asked to add as many pairs as
possible within an allotted 4-min test opportunity.
Analysis of plasma melatonin. The timing of the plasma
melatonin rhythm at the beginning of the protocol and during the
constant routine at the end of the protocol was assessed by: 1) the
onset of plasma melatonin secretion (the clock-time when the
plasma melatonin concentration rose above 43.1 pmol/L) [33]; 2)
the time at which rising levels crossed the individual’s 24-h mean
value; 3) the time at which falling levels crossed the individual’s 24-
h mean value; and 4) the midpoint between the upward and
downward mean crossing [34]. The duration of the secretory
phase of the melatonin rhythm was defined as the width of the
melatonin peak, i.e. the interval between the upward and
downward mean crossing. The amplitude of the melatonin
rhythm was assessed by computing the area under the curve
(AUC) using the trapezoid method, and applying it to a standard
segment of the melatonin curve, from 8 h before the midpoint
until 8 hours after the midpoint of the melatonin rhythm. Baseline
values, defined as the average plasma melatonin concentration in
the interval 12-8 h before and 8–12 h after the melatonin
midpoint, were subtracted from the data prior to computing
AUC. The change of amplitude of the melatonin rhythm was
assessed as the change in AUC between day 2 and day 9, with the
value during day 2 set as 100% [100*((AUC Day9-AUC Day2)/
AUC Day2)].
Analysis of core body temperature. In each subject the
endogenous circadian phases and amplitude of the core body
temperature data collected during the constant routine was
determined by fitting a harmonic regression model in which it is
assumed that the data can be described by a fundamental
circadian sinusoid and its first harmonic as well as serially-
correlated noise [35]. The first five hours and the final half hour of
temperature data from the constant routine were excluded from
analysis to eliminate masking effects of awakening from sleep and
the masking associated with the preparation for the sleep episode
following the constant routine.
Analysis of plasma cortisol. Phase and amplitude of
individual cortisol profiles during the 24-h baseline period and
the first 24-h period of the constant routine were assessed by
indentifying the maximum and the minimum after the time series
was smoothed by a 2-h running average. In addition, the phase,
mesor and amplitude of plasma cortisol data, averaged per group,
were estimated by fitting a sine wave and linear function to the
data using PROC NLIN (SAS H Institute Inc., Cary, NC, Version
6.12 or later).
Analysis of alertness and performance. Phase and
amplitude of individual alertness and performance profiles
during the constant routine were assessed by fitting the function
Var=C+L*time+ A*sinus ([phase-time]/24.2) as implemented in
PROC NLIN (SAS) to the data. In the function, C represents a
constant, L the linear change in alertness or performance with
time awake, A the amplitude of the circadian modulation of
performance, and Phase the estimated maximum of the circadian
modulation of alertness or performance.
Analysis of association between amplitude reduction in
melatonin and the amplitude of other rhythms. To assess
the association in changes in amplitude across variables we
proceeded in two ways. First, in each individual, amplitudes of all
variables were assessed separately and associations between those
amplitudes were assessed using a correlation.
Second, participants (regardless of group) were divided into
those who showed a suppression of melatonin greater than 50%
and those who did not. Next, the average waveforms of other
variables (core body temperature, cortisol, subjective alertness,
performance) were computed for each melatonin suppression
group. In this analysis, all variables were referenced relative to the
timing of the core body temperature minimum observed during
the CR.
Analysis of sleep data
An estimate of the effect of the light exposure group on sleep
was obtained by analyzing polysomnographically-assessed sleep
parameters from the 7th and 8th sleep episodes, i.e., the last two
sleep episodes before the constant routine when sleep timing was
advanced by 10 h. In one subject, the data of sleep episode 8 could
not be scored due to technical problems. Sleep latency data were
log-transformed in order to be normally distributed prior to
statistical tests.
Statistical methods
SAS H (SAS Institute Inc., Cary, NC, Version 6.12 or later)
mixed model analyses of variance (PROC MIXED) and paired
and unpaired two-tailed Student t-test were used as appropriate to
assess the significance of phase and amplitude differences between
groups. Factors in these analyses were Group (Moderate Light,
Bright Light) and Day (Day 2, Day9) or Sleep Period (SP 7, SP 8),
the latter factors being repeated.
The phase and 95% confidence intervals of the circadian
rhythms of alertness and performance were estimated by fitting the
data to a combined sine function and linear function using a
nonlinear regression procedure (PROC NLIN). Associations
between variables were assessed by Kendall Product Moment
correlations (PROC CORR).
Amplitude Reduction of Multiple Circadian Rhythms
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Effects of treatment group on circadian phase were analyzed by
assessment of the timing of individual phase markers (Table 1,
Fig. 2) and by analyzing the average waveform of these variables
for the two groups separately (Fig. 3).
Plasma melatonin phase
The mixed model ANOVA yielded a significant effect of
Group and Day as well as a significant interaction between these
factors for the melatonin phase assessed by DLMO, upward
crossing, midpoint, and downward crossing (p,0.001 for all
variables and all effects). Contrast analyses revealed that the
timing of the plasma melatonin rhythm as assessed by these four
phase markers was not significantly different (p.0.3 in all cases)
between the two groups at the baseline assessment on Day 2–3,
with a rise in plasma melatonin levels occurring prior to bed
time, and peak levels during the scheduled sleep episode (see
Table 1 and Fig. 2 and 3). On study Day 9 following the advance
of the sleep schedule, the timing of the onset, upward mean
crossing, midpoint, and downward mean crossing of the plasma
melatonin rhythm was significantly different between the two
groups (p,0.001 in all cases). In the bright light group, each of
the phase markers of the plasma melatonin rhythm had
advanced significantly compared to the baseline assessment
(p,0.001 for all phase markers) by at least 8 h (see Table 1),
such that it was rising prior to and peaking in the middle of the
advanced sleep episode. In contrast, in the moderate light group
the timing of the melatonin rhythm did not change significantly
from the baseline assessment (p.0.3 in all cases; see Table 1).
This resulted in the peak of melatonin secretion occurring on
average after scheduled wake time in the moderate light group
(see Fig. 3). Note that for two participants in the moderate light
group (1025 and 1141) we were not able to assess phase of the
melatonin rhythm after the intervention, because the amplitude
of the melatonin rhythm was so small that the DLMO and other
phase markers could not be assessed reliably. These two subjects
showed robust amplitudes of their melatonin rhythm on Day
Two. Information on the phase shifts for each participant is
presented in Table S1.
Plasma cortisol phase
The mixed model ANOVA yielded a significant effect of Group,
a significant effect of Day, and a significant interaction between
these factors for the timing of the cortisol rhythm as assessed from
the maximum or minimum (p,0.02 in all cases). Contrast analyses
demonstrated that the timing of the plasma cortisol rhythm was
not significantly different between the two groups at the baseline
assessment on Day 2–3 (p.0.3 in all cases), with the minimum of
plasma cortisol levels occurring around bed time, and peak levels
occurring at the beginning of the wake episode (see Table 1 and
Fig. 2 and 3). On study Day 9 following the advance of the sleep
schedule, the timing of the minimum and maximum of the plasma
cortisol rhythm was significantly different between the two groups
(p,0.001). In the bright light group, the minimum of the plasma
cortisol rhythm had significantly advanced (p,0.001) by on
average 10 hours, such that it remained coincident with the
beginning of the scheduled sleep episode. In contrast, in the
moderate light group the timing of minimum of the cortisol
rhythm did not change significantly (p.0.2) from the baseline
assessment (see Table 1) with an average advance of only 2 hours.
Analysis of the average waveform (Fig. 3) revealed that at the end
of the experiment in the bright light group the scheduled sleep
episode coincide with the rising limb of the cortisol rhythm, similar
to the baseline condition. In contrast, the maximum of the average
waveform of cortisol in the moderate light group was located at
7:58 (95% CI 7:26–8:32), which was well before the beginning of
the scheduled sleep episode. Thus in the moderate light group the
scheduled sleep episode coincided with the declining limb of the
cortisol rhythm (see Fig. 3).
Core body temperature phase
On Day 9 after the gradual sleep/wake schedule inversion, the
temperature minima measured during constant routines occurred
significantly earlier in the bright light group than in the moderate
light group (22:0261:15 h vs. 03:4361.01 h; p,0.005). The
timing of the temperature rhythm was such that in the bright light
group the nadir occurred near the end of the scheduled sleep
episode, while in the moderate light group the temperature nadir
occurred on average 5.5 h after the scheduled wake time (see
Fig. 3).
Alertness and performance phase
Alertness and Performance both exhibited a decline during the
CR associated with the extended duration of wakefulness.
Following $16 hours of wakefulness, alertness levels appeared to
co-vary with the core-body temperature rhythm (illustrated for
alertness in Fig. 3). After approximately 24 hours awake,
subjective alertness co-varied with the core-body temperature
cycle in both groups (see upper panels of Fig. 3), such that in the
bright light group the first observed minimum was located close to
the end of the scheduled sleep episode, whereas in the moderate
light group it was located several hours later, after the beginning of
Table 1. Timing of circadian phase markers.
Moderate Light Bright Light
Phase
marker D2 CR D2 CR
DLMO
111 22:54
(7;0:27)
22:03 (5;0:53) 22:55
(7;0:14)
14:49
(7;0:47)###
Mel-Up
111 23:32
(7;0:23)
22:43 (5;1:01) 23:48
(7;0:09)
14:39
(7;0:47)###
Mel-Down
111 08:52
(7;0:28)
07:07 (5;0:57) 08:22
(7;0:13)
22:12
(7;0:58)###
Mel-Mid
111 04:12
(7;0:23)
02:57 (5;0:59) 04:05
(7;0:09)
18:26
(7;0:52)###
Cortisol-Min
111 01:05
(6;0:46)
22:49 (5;01:46) 00:36
(7;0:52)
14:25
(7;0:41)###
Cortisol-Max
111 09:04
(6;0:34)
05:25 (5;02:36) 09:00
(7;0:41)
22:05
(7;0:19)###
Temp-Min
11 NA 03:43 (7;01:01) NA 22:02 (7;01:15)
Alert-Min NA 01:26 (7;01:41) NA 22:17 (7;01:17)
Perfor-Min NA 04:13 (7;01:18) NA 0:08 (7;01:30)
Timing [h:min (n;SEM)] of Dim Light Melatonin Onset (DLMO), melatonin-
upward, melatonin midpoint, and melatonin downward crossing, cortisol
minimum, cortisol maximum, core-body temperature minimum, alertness and
performance minimum at baseline (D2) and during the Constant Routine (CR) in
the Moderate Light and Bright Light condition. Minima for Alertness and
Performance are the minima of the circadian component.
###p,0.001: D2 vs. CR;
11:p ,0.01;
111:p,0.001 Moderate Light vs. Bright Light during CR.
P values were derived from two factor Mixed Model ANOVA for those variables
for which estimates were available at Baseline and During the CR or Students t-
test for those variables for which estimates were available during the CR only.
doi:10.1371/journal.pone.0030037.t001
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e30037Figure 2. Plasma melatonin and cortisol rhythms. Plasma melatonin and cortisol rhythms before (Baseline – SP2 – upper panels) and after
(Constant Routine – lower panels) the gradual shift of the sleep-wake schedule, in a participant treated with moderate light (1262V) and a participant
treated with bright light (1110V). The vertical solid lines indicate the eight-hour scheduled sleep/darkness episode (SP2) on the baseline day (D2), the
dotted vertical lines indicate the projected eight hour sleep episode (based on the sleep period of the preceding night) during the constant routine.
doi:10.1371/journal.pone.0030037.g002
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yielded an estimate of the timing of the minimum in the bright
light group at 22:18 h (95% CI 20:58–23:39), just after scheduled
wake time, whereas in the moderate light group the minimum of
the average curve of alertness occurred at 03:32 h (95% CI 2:03–
5:03), more than 5 hours after scheduled wake time. Alertness
levels then improved, coincident with the rising limb of the core
body temperature rhythm. Analysis of the calculation performance
data showed that the minimum of the average curve of
performance in the bright light group occurred at 00:59 h (95%
CI 23:33–02:26), whereas it occurred three hours later in the
moderate light group (03:59 h; 95% CI 02:53–05:06). This
analysis at the group level was consistent with the analysis of the
timing of the minima on an individual basis, although in that
analysis only the difference in the timing of the minimum for
performance was significantly different between the groups
(Table 1).
Individual differences in the timing of circadian rhythms
after the intervention: association across variables
We examined the association between individual differences in
the timing of the various variables during the CR, independent of
the treatment group and found that they were highly correlated
(Fig. 4). Thus, the correlation between the timing of the minimum
of the core-body temperature and the cortisol minimum was 0.766
(n=12; p=0.004) whereas the correlation with the cortisol
maximum was 0.605 (n=12; p=0.037). The correlation between
the body temperature nadir and various indices of melatonin
phase was 0.871 (p,0.001) for the timing of the melatonin
midpoint, and 0.907 (p=,0.001) for the DLMO. The timing of
Figure 3. Average waveforms of circadian variables after moderate and bright light treatment. Time course of core body temperature,
plasma melatonin, cortisol and subjective alertness during the constant routine in moderate light and bright light treated participants. Subjective
alertness data were averaged per 2-h bins. All date are referenced to the projected wake time (22:00 clock-time). Box indicates the timing of the sleep
episode on the previous day. Data represent means+/2 SEMs.
doi:10.1371/journal.pone.0030037.g003
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the minimum of the circadian component of alertness (r=0.730;
p,0.005) as well as the minimum component of performance
(r=0.833; p,0.001).
Melatonin amplitude
Visual inspection of the melatonin profiles revealed that in some
subjects no discernible rhythm was present during the CR despite
robust rhythmicity at baseline. These reductions were observed in
both treatment groups (for two examples see Fig. 5; Table 2 for
averages per treatment group).
Mixed model ANOVA yielded a significant effect of Day for
the height of the melatonin rhythm (p,0.004), the area under
the curve (P,0.001), the average melatonin concentration
(p,0.0003), as well as the width of the melatonin rhythm
(p,0.01) with no significant effect of Group (p.0.09 in all cases)
and no significant interaction between these two factors (p.0.5 in
all cases). The average reduction of the area under the curve (CR-
D2 expressed as percentage of the value at D2) was 53.6% (n=7;
SEM=12.1%) in the moderate light and 51.7% (n=7;
SEM=10.5%) in the bright light group. For the height of the
melatonin rhythm the reductions were 43.6% (7; 13.8) and 44.0%
(7; 9.5) for the moderate light and bright light condition
respectively. For the duration (width) of the melatonin secretion
phase the reductions were 12.9% (5; 7.6) and 12.0% (7; 2.7) for the
moderate light and bright light condition respectively. Thus,
several amplitude measures of the melatonin rhythm as assessed
under constant-routine conditions following a gradual advance of
the sleep-wake cycle were significantly reduced compared to the
amplitude assessed at baseline in the presence of a sleep-wake
cycle. Information on the change in melatonin amplitude for each
participant is presented in Table S1.
Cortisol amplitude
Several amplitude measures of the cortisol rhythm were also
affected by the protocol (Table 2). A significant effect of Day was
observed for the minimum of the cortisol rhythm (p=0.01), with
no significant effect of condition (p=0.45) or interaction
(p=0.063). The minimum of the cortisol rhythm was significantly
higher on Day 9 compared to Day 2 (p=0.01) with an average
increase (CR-D2 as % of D2) of 165.8% (5;26.8) in the moderate
light and 54.7% (7;39.5) in the bright light group.
The area under the curve was significantly greater (p=0.039)
on Day 9 compared with Day 2. No effect of Group (p=0.78) or
interaction (p=0.36) was observed for this measure and the
average increase was 25.6% (5;6.1) and 11.4% (7;10.1) in the
moderate light and bright light group respectively.
Core body temperature, alertness and performance
amplitude
For core body temperature, alertness and performance,
circadian amplitude could only be assessed during the Constant
Routine (Table 2). No differences between groups were observed
for any of these variables, and in both groups a wide range of
amplitude values were observed across individuals.
Figure 4. Association between the timing of circadian vari-
ables. Association between the timing of melatonin midpoint, cortisol
minimum, circadian minimum of alertness and performance and the
timing of the temperature minimum during the constant routine in
participants exposed to moderate light (filled symbols) or bright light
(open symbols).
doi:10.1371/journal.pone.0030037.g004
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e30037Figure 5. Examples of amplitude reduction. The plasma melatonin (filled symbols) and cortisol rhythm (open symbols) during the baseline day
and SP2 and the constant routine (Day 9–10) in a bright light (1134) and moderate light (1141) treated subject. In both participants a reduction of the
plasma melatonin amplitude as well as changes in the cortisol rhythm can be observed.
doi:10.1371/journal.pone.0030037.g005
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amplitude of other rhythms
The amplitude reduction as measured by area under the
melatonin curve varied considerably between subjects in each
group. In the bright light group it varied from 12.3–84.3%
whereas in the moderate light group the range was 16.6–93.7%.
To investigate whether reduction of melatonin amplitude was
associated with changes in the amplitude of other rhythms we
proceeded in two ways. We first divided subjects into those with
greater (.50%, n=7) or less (,50%, n=7) reduction in
melatonin amplitude between Day 2 and Day 9 and compared
the average waveforms of melatonin, core body temperature,
cortisol, and alertness between these two groups (Fig. 6). We then
assessed the correlations between the amplitude measures of these
variables at an individual level (Fig. 7). In the stronger suppressors,
the amplitude reduction was primarily related to a reduction of the
maximum of melatonin secretion and not due to an increase in the
baseline (see lower panel of Fig. 6). As a group, the strong
suppressors showed a significantly lower core body temperature
amplitude, demonstrated by a lower fitted mesor of the average
core body temperature curve (Stronger suppressors: 37.03uC;
95%CI: 37.02–37.05; vs. Weaker suppressors: 37.09; 95%CI:
37.07–37.11) and a lower fitted core body temperature amplitude
(Stronger suppressors: 0.23uC; 95%CI:0.22–0.25; Weaker sup-
pressors: 0.29; 95%CI:0.27–0.31; Fig. 6). A significant correlation
between melatonin amplitude reduction and the amplitude of the
core body temperature rhythm was observed (n=14, r=0.58;
p=0.028; Fig. 7).
The cortisol amplitude also differed between the stronger and
weaker melatonin suppressors. In the stronger suppressors, the
fitted mesor of the plasma cortisol rhythm was significantly lower
than in the weaker suppressors (Stronger Suppressors: 10.15 ug/
dL, 95%CI: 9.70–10.60; Weaker Suppressors: 11.83 ug/dL, 95%
CI: 11.28–12.37), and the amplitude of the cortisol rhythm was
also significantly lower (Stronger Suppressors: 3.35 ug/dL,
95%CI: 2.73–3.97; Weaker Suppressors: 5.54 ug/dL; 95% CI:
4.80–6.29; Fig. 6). The correlation between the change in
amplitude of cortisol, defined as the difference between minimum
and maximum, and the change in amplitude in melatonin was
0.57 (n=12; p=0.051; Fig. 7).
Suppression of the plasma melatonin rhythm also affected the
time course of performance and alertness, such that the stronger
suppressors showed a near linear decline in alertness with time
awake, while the weaker suppressors showed a marked deteriora-
tion of alertness coinciding with the peak of the melatonin rhythm,
in addition to the linear trend (see upper panel of Fig. 6). The
overall amplitude of the alertness rhythm was significantly lower in
the stronger suppressors (Stronger Suppressors: 4.59 mm, 95% CI:
1.27–7.90; Weaker Suppressors: 16.93 mm, 95% CI: 11.60–
22.27). Overall the stronger suppressors were more alert
throughout the extended wake episode on Day 9, and their
average waveform of alertness had a mesor of 46.25 mm (95%CI
43.93–48.56) vs. 39.88 mm (95%CI 36.17–43.59) in the weak
suppressors. The correlation between the change in amplitude of
melatonin and the amplitude of alertness was 0.52 (n=14;
p=0.058; Fig. 7). The fitted amplitude of the performance rhythm
was also lower for the stronger suppressors (stronger suppressors:
6.7 calculations attempted, 95%CI 3.5–9.8; weaker suppressors:
10.4 calculations attempted, 95%CI 6.4–14.5, See Fig S1). The
correlation of the estimates of amplitude for this measure did
however not correlate significantly with melatonin suppression.
It should be noted that a reduction in the amplitude of the
alertness rhythm resulted in higher alertness during the biological
night in the stronger melatonin suppressors.
Comparison of sleep in moderate light and bright light
groups
Sleep parameters averaged across sleep periods 7 (SP-7) and 8
(SP-8) are presented in Table 3. Mixed model ANOVA with
factors Group and Sleep-Period revealed a significant effect of
Group on sleep latency (p,0.04) with no significant effect of
Sleep-period or interaction between these factors. The average
sleep latency on Nights 7 and 8 (after the sleep episode had been
advanced by 10 h) was less than 5 minutes in the moderate light
group, significantly shorter than sleep latency in the bright light
group (Table 3).
No significant difference in total sleep time was observed between
the two groups, but wake after sleep onset (WASO) tended to be
lower in the bright light group (p,0.07). This reduction of WASO
in the bright light group was accompanied by a significant increase
in the duration of stage 2 which was particularly pronounced during
SP-8 (stage 2 during SP-8 Bright Light vs. Moderate Light:
p=0.012). No significant difference in the duration of SWS was
observed,but the duration of stage 4 wasshorter and the percentage
of SWS was lower in the bright light group than in the moderate
light group and in particularly so during SP-8 (SWS% during SP-8
Bright Light vs. Moderate Light: p=0.014).
Comparison of sleep in strong and weak melatonin
suppressors
Sleep parameters were compared in subjects in whom
melatonin amplitude was reduced by more than 50% to those in
whom it was less reduced. A mixed model ANOVA with factors
Melatonin-suppression and Sleep-period did not yield a significant
effect for the factor Melatonin-suppression for any of the sleep
parameters. However, the interaction between the factor Melato-
nin-suppression and Sleep-period was significant for TST
(p,0.05), Stage Three (p,0.03), Stage Four (p,0.01) and SWS
Table 2. Amplitude measures of circadian markers.
Moderate Light Bright Light
D2 CR D2 CR
Mel AUC 98.1 (7;6.7) 47.6 (7;13.1)## 93.7 (7;14.1) 45.8 (7;13.4)##
Mel Height 228.7 (7;11.4) 133.9 (7; 34.4)# 250.9 (7; 41.2) 142.8 (7;
34.9)##
Mel Width 9:19 (7;0:24) 8:11 (5; 0:26) 8:35 (7; 0:12) 7:34 (7; 0:21)##
Cort AUC 215.7 (6;15.65) 262.4(5; 25.32)# 221.7 (7; 23.8) 244.1(7; 30.4)
Cort Min 1.54 (6; 0.18) 3.94 (5; 0.76)## 2.13 (7; 0.47) 2.61 (7; 0.38)
Cort Max 18.22 (6; 1.72) 18.70 (5; 1.75) 18.74 (7; 1.83) 19.53 (7; 2.17)
Cort Range 16.68 (6; 1.72) 14.76 (5; 2.07) 16.61 (7; 1.41) 16.92 (7; 2.0)
Temp Amp NA 0.27 (7;0.03) NA 0.30 (7;0.02)
Alert Amp NA 10.85 (7; 3.31) NA 9.49 (7; 2.11)
Perf Amp NA 8.83 (7;2.8) NA 6.51 (7;1.0)
Amplitude measures for melatonin (Mel), cortisol (Cort), core body temperature
(Temp), alertness (Alert) and performance (Perf) on D2 and the CR separately for
the moderate light and bright light treatment group. Melatonin height: pmol/L;
Melatonin area under the curve (AUC) nmol/L*min; Melatonin width: h:min.
Cortisol measures are in mg/dL, temperature measures in degrees Celsius,
Alertness in mm and Performance in number of additions attempted.
##p,0.01 CR vs. D2 per treatment group (see text for overall statistical
significance for effect of Day (i.e. CR vs. D2). For core body temperature,
alertness and performance data were not available (NA) during D2.
doi:10.1371/journal.pone.0030037.t002
Amplitude Reduction of Multiple Circadian Rhythms
PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e30037(p,0.01). This interaction primarily represented a significant
increase of TST (LSMEANS estimate: 95.8 min, SEM 31.4,
P,0.01) from sleep period 7 to 8 in the group in which melatonin
was only moderately suppressed and a reduction of Stage Three
(14.8 min, SEM: 6.8; P=0.05), Stage Four (25.4 min, SEM: 7.8;
P,0.01) and SWS (40.1 min, SEM:11.8; P,0.01) from sleep
period 7 to 8 in the group in which melatonin was strongly
suppressed.
Discussion
Contribution of bright light and moderate light to
maintaining synchrony of endogenous circadian rhythms
with advanced sleep-wake cycle
The present data show that when the sleep-wake cycle is
gradually advanced over several days and the associated light-
dark cycle consists of only moderate light, multiple circadian
rhythms desynchronize from the sleep-wake and light-dark cycle.
This indicates that on average the drive of moderate light and
the sleep-wake cycle onto the circadian pacemaker is insufficient
to induce a phase advance of 2 h per day. By contrast, exposure
to bright light for several hours following the sleep episodes
facilitated the maintenance of the normal phase relationship
between multiple circadian rhythms and the shifted sleep-wake
cycle. The pattern of bright light exposure was designed to cause
daily phase advance shifts sufficient to overcome the 0.2 h daily
phase delay that would be expected based on the 24.2-h average
period of the human circadian system [36] and the additional
2 h daily shift related to the advancing sleep-wake cycle. This
bright light exposure schedule led to a phase advance of the
melatonin rhythm in all participants, although individual
differences were observed. In comparison, in the moderate light
Figure 6. Average waveforms of circadian variables and amplitude reduction. Average waveform of subjective alertness, plasma cortisol,
core body temperature and plasma melatonin during a constant routine in participants with a reduction in melatonin amplitude .50% (closed
symbols; n=7) compared to those in whom the reduction was ,50% (open symbols; n=7). All data are aligned with the timing of the fitted
minimum of the core body temperature rhythm. Error bars indicate 1 SEM.
doi:10.1371/journal.pone.0030037.g006
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melatonin rhythm was observed, and some individual differences
were present. Importantly, no phase delays were present in the
moderate light treatment group indicating that the drive of the
sleep-wake cycle and moderate light onto the circadian pace-
maker was sufficient to counteract the phase delay associated
with an average intrinsic period of 24.2 h, in accordance with
studies showing that dim light is sufficient to maintain
entrainment to the 24-h cycle [37]. Other studies using a
progressively advancing schedule have reported effects of
exposure to moderate light and shifted sleep-wake cycles on
circadian rhythmicity [23,24,38] and taken together these data
indicate that moderate light and feedback from the sleep-wake
cycle exert a small drive onto the pacemaker, however that drive
was insufficient to advance the circadian system by 2 h per day
in our study.
Individual differences in timing of circadian rhythms after
bright and moderate light exposure: changes in circadian
phase are similar for multiple variables
The assessment of the endogenous circadian phase of multiple
rhythms under constant routine conditions at the end of the
protocol indicated that individual differences in the timing of the
rhythms were highly correlated across variables. This implies that
under both light conditions the phase shifts of body temperature,
plasma melatonin, plasma cortisol and alertness were of similar
magnitude. This corroborates previous findings [39] [8] [25,40]
and indicates that all these rhythms are driven by the same light-
sensitive pacemaker, presumably the SCN. This simultaneous
change in the timing of multiple variables is likely to be mediated
by the identified pathways from the SCN to the effector organs,
i.e. pineal and adrenal cortex have been described, although the
mechanisms by which the SCN regulates core body temperature
alertness and performance is less clear.
Reduction in circadian amplitude: correlation across
variables
All amplitude measures of the melatonin rhythm indicated a
reduction in circadian amplitude during the constant routine
following the sleep-wake schedule inversion compared with the
amplitude at baseline, i.e. in the presence of a sleep-wake and
dark-light cycle. The reduction in amplitude primarily reflected a
reduction in the maximum values of melatonin rather than an
elevation in minimum values. On average, the change in
melatonin amplitude did not differ between the bright light and
moderate light groups and the large range of inter individual
differences in range of amplitude changes was similar in the two
groups. Amplitude reduction in melatonin was associated with
lower amplitude of body temperature and cortisol. Whereas for
body temperature the amplitude reduction represented elevated
minima and reduced maxima, the change in cortisol amplitude
appeared more related to elevated minima, although a reduction
in maximum values cannot be excluded.
Circadian desynchrony and amplitude reduction: effects
on alertness, performance and sleep
Sleep and alertness and performance during wakefulness are
determined by an interaction of circadian rhythmicity and sleep-
wake homeostasis, such that consolidation of sleep and wakefulness
depends on an appropriate phase relationship between the sleep-
wake cycle and endogenous circadian rhythmicity [41]. According
to this concept, a wake-promoting signal which becomes
progressively stronger during the biological day opposes the
decline in alertness and performance associated with sustained
wakefulness. At the end of the biological day, this wake promoting
signal dissipates and under normal conditions sleep will be
initiated. However, if wakefulness is sustained beyond a typical
,16 h wake episode, as was the case in our protocol or during
night shift work, alertness and performance will deteriorate. The
present data show that appropriate timing of the maximum of
alertness and performance relative to the sleep-wake cycle
correlates with the appropriate timing of other circadian rhythms
such as melatonin. In the initial part of the constant routine, no
differences between the two groups were observed but when the
duration of prior wakefulness increased, differences between the
two groups emerged. During the projected sleep episode, the light-
treated group exhibited the adaptive decline of alertness with a
minimum shortly after the minimum of the core body temperature
rhythm, whereas in the control group alertness, and to a lesser
extent performance, remained high in the initial part of the
Figure 7. Association between the amplitude of circadian
variables. Association between the amplitude of body temperature,
cortisol, and alertness during the constant routine and the reduction in
the amplitude of melatonin in participants exposed to moderate light
(filled symbols) or bright light (open symbols).
doi:10.1371/journal.pone.0030037.g007
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10 hours into the scheduled wake-episode. This time-course is
consistent with previous reports of the interaction of circadian and
wake dependent determinants of alertness and performance [42]
[43] and with the observed phase differences between the two
groups for other variables like melatonin, body temperature and
sleep propensity.
The current data also show that when the amplitude of circadian
rhythms is reduced, alertness and performance decline in a near
linear manner during sustained wakefulness, i.e. the homeostatic
component dominates the time course. Interestingly, this reduced
circadian amplitude leads to higher levels of alertness and
performance during the circadian night. The implication from this
is that a reductionofcircadian amplitudemay facilitate the abilityto
stayawakeat night, andthat beingbetter-able tostayawakeatnight
may be indicative of a reduced circadian amplitude.
Analysis of sleep propensity and structure by polysomnography
corroborated the interpretation that bright light treatment led to a
more appropriate phase relationship between the scheduled sleep-
wake cycle and endogenous circadian rhythmicity. In the
moderate light group, the scheduled sleep episode was located
before the onset of melatonin secretion and coincided with the
plateau of the core body temperature rhythm. In contrast, in the
bright light treatment group the scheduled sleep episode coincided
with the phase of melatonin secretion and the falling limb on the
core body temperature rhythm, as is usual during entrainment [2].
This difference in the phase relationship between the circadian
system and scheduled sleep was associated with differences
between the two groups on a number of sleep measures. Wake
after sleep onset was lower in the bright light-treated group
compared with the moderate light group. This finding is in
accordance with observations from forced desynchrony experi-
ments [44] [45] [46], which demonstrated that sleep consolidation
in young adults can be maintained for 8 hours when sleep is
initiated just after the onset of melatonin secretion, on the falling
limb of the core body temperature rhythm.
The observation that sleep latencies were longer in the bright
light group may at first glance seem to be at odds with the notion
that the near normal phase relationship between sleep and
circadian rhythmicity in this treatment group improves sleep. A
variety of protocols have demonstrated that the circadian rhythm
of sleep propensity reaches its nadir during the latter part of the
habitual waking day, such that shortly before habitual bedtime, i.e.
just before the onset of melatonin secretion the circadian drive for
wakefulness is strongest [44,47] When we are normally entrained,
this circadian drive for wakefulness near the end of the habitual
waking day results in a ‘‘wake maintenance zone’’ [48] or
‘‘forbidden zone for sleep’’ [49], which not only allows us to
remain awake despite having been awake for many hours, but
makes it difficult to fall asleep quickly. Thus, participants in the
light treatment group, who exhibited a normal phase of
entrainment at the end of the protocol, showed normal sleep
latencies. In contrast, the moderate light participants showed
significantly shorter sleep latencies. Because the timing of their
circadian rhythms had not changed significantly while the timing
of their sleep had advanced by 10 hours, they were initiating sleep
in the ‘circadian afternoon’, a circadian phase at which the drive
for waking is only moderate. This, together with cumulative sleep
disruption on the prior advanced sleep episodes, likely contributed
to the very short sleep latencies in the moderate light group.
Although no major effects of moderate and bright light treatment
or amplitude reduction on sleep structure were observed, some
effects were puzzling. These include the increase in stage four sleep
in the moderate light group as well as the reduction of SWS from
sleep period 7 to 8 in the participants in whom melatonin was
strongly suppressed. These findings are surprising because the
effects of circadian parameters on SWS are thought to be minor
[41].
Overall, the sleep and waking performance data corroborate the
notion that the protocol and the bright light treatment affected the
circadian system in a coherent way, i.e. shifted or reduced the
amplitude of all aspects of the endogenous day-night cycle.
Table 3. Polysomnographically assessed sleep parameters in the Moderate Light and Bright light group.
Moderate Light Bright Light Moderate vs. Bright
Sleep Latency (min) 4.6 (1.6) 18.4 (9.8) P=0.04
REMS Latency (min) 49.2 (9.4) 64.5 (5.3) NS
Total Sleep Time (min) 348.4 (12.6) 380.6 (19.7) NS
Wake After Sleep Onset (min) 128.0 (12.7) 81.3 (19.0) NS
Stage 1 (min) 33.5 (3.2) 39.8 (2.9) NS
Stage 2 (min) 147.1(8.6) 187.8 (12.2) P=0.02
Stage 3 (min) 32.0 (4.4) 37.9 (6.1) NS
Stage 4 (min) 70.2 (11.6) 31.2 (13.5) P=0.05
Slow Wave Sleep (min) 102.1 (11.7) 69.1 (17.9) NS
REM Sleep (min) 65.6 (4.5) 83.9 (8.8) NS
Movement Time (min) 2.8 (1.0) 3.4 (1.2) NS
Stage 1% 9.9 (0.9) 10.9 (0.8) NS
Stage 2% 42.2 (2.4) 49.8 (3.1) NS
Slow Wave Sleep % 29.4 (2.9) 17.8 (3.9) P=0.4
REM Sleep % 18.6 (1.0) 21.6 (1.9) NS
Mean and SEMS for sleep parameters for the two treatment groups. Data represent the averages of sleep episodes 7 and 8 for all subjects, with the exception of subject
1041 from the Bright Light group in whom only sleep episode 7 was included. n=7 in each condition. % represents the percentage of that sleep stage expressed
relative to total sleep time. P values indicate the significance of the difference between the Treatments as assessed in a two-factor Mixed Model ANOVA with factors
Treatment and Sleep period. Sleep latency data were log-transformed prior to statistical tests.
doi:10.1371/journal.pone.0030037.t003
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multiple variables: Interpretation
The protocol led to changes in melatonin amplitude which were
accompanied by changes in the amplitude of the rhythms in
alertness, performance, core body temperature and cortisol,
suggesting that broad aspects of circadian organization were
affected. These observations highlight the disruptive effects of
altered sleep-wake timing and light exposure on the temporal
organization of physiology and behavior. Such disruptive effects
are thought to be associated with negative health outcomes. Thus
melatonin suppression is thought to mediate some of the negative
effects of shiftwork on health [50]. The question remains how to
interpret these effects on circadian amplitude within current
conceptual frameworks of circadian organization. Traditionally a
distinction is made between endogenous and exogenous compo-
nents of overt rhythmicity. The suppression of the amplitude of
multiple rhythms observed in the present protocol could
conceivably reflect the direct effect of the continuous ,90–
150 lux moderate light exposure during the assessment on Day 9.
That level of illuminance has previously been shown to exert a
direct suppressive effect on melatonin [16],[14,51] and influence
alertness [17] although for cortisol effects of light have previously
only been investigated for much higher illuminances [52] . It
should be noted though that human circadian rhythmicity is in
general considered to be robust under these constant conditions.
The extent to which light influences melatonin suppression
differs between individuals [14] and depends on the light exposure
history [18,20,53]. In a prior study conducted in our laboratory,
we found that exposure to a 200 Lux light stimulus had more of a
suppressive effect when participants were previously exposed to
2 lux, compared to when they were previously exposed to 200 lux
[53]. The latter conditions is more comparable to the present
study, because during the days preceding the melatonin assessment
on Day 9, participants in the present study were exposed to light of
the same (,90–150 lux) illuminance.
An alternative interpretation of the observed reduction of
circadian amplitude is that this reflects a change in the amplitude
of the circadian system in response to the perturbation of
entrainment. According to this interpretation, the shifted sleep-
wake cycle and pattern of light and darkness prior to the
assessment on Day 9 may have led to a reduction of the amplitude
of the circadian pacemaker. During the sleep/wake schedule
inversion, even the moderate light participants were exposed to
light at times when the circadian system is most sensitive to light. It
is therefore possible that the exposure to ambient moderate light
exerted a sufficiently strong drive onto the pacemaker to suppress
the amplitude of the circadian pacemaker itself in some of the
participants. If so, this would be comparable to the amplitude
reduction of core body temperature [10] and plasma melatonin
[54] rhythms that we observed in some participants after exposure
to critically-timed bright light.
As discussed elsewhere, such a reduction in amplitude may
either reflect desynchrony of the individual neuronal oscillators
which comprise the master pacemaker, desynchronisation between
the central and peripheral oscillators, or a reduction of the
amplitude of synchronized individual oscillators at the molecular
level [55]. Of interest is that in humans light has been reported to
directly induce the expression of PER2 in leukocytes [56], and a
reduction of the amplitude of canonical clock genes has been
observed after exposure to light in the Siberian hamster [57].
Whatever interpretation is correct, our findings demonstrate
large inter-individual differences in the disruptive effects of the
protocol on circadian organization. In real life, people are exposed
to altered light dark and sleep-wake cycles during shift-work and
time-zone travel. The present data and other recent data [14,51]
suggest that such schedules together with the associated light
exposure can substantially reduce the amplitude of multiple
circadian rhythms, and that individuals differ in their response.
Whether and how this relates to individual differences in
complaints and negative health outcomes associated with jet lag
and shift-work remains to be established.
Supporting Information
Figure S1 Average waveform of performance during a
constant routine in participants with a reduction in
melatonin amplitude .50% (closed symbols) compared
to those inwhomthe reductionwas,50% (open symbols).
All data are aligned with the timing of the fitted minimum of the
core body temperature rhythm. Error bars indicate 1 SEM.
(TIF)
Table S1 Individual values of the change in melatonin
amplitude as well as the timing of the melatonin
midpoint. See main text for detail. Time is in decimal hours,
28.5=04:30AM.
(DOCX)
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